Table 1. Characteristics of patients with hepatocellular carcinoma (n = 69).

Variable	Total (n = 69)	Recurrence (n = 32)	Non-recurrence (n = 37)	P-value
Sex (M:F)	51:18	24:8	27:10	1.000
Age (years)	60.2 ± 10.9	60.3 ± 8.5	60.2 ± 12.7	0.971
Body mass index	24.6 ± 3.4	24.5 ± 4.1	24.7 ± 2.8	0.785
Alcohol	18.8% (13/69)	15.6% (5/32)	21.6% (8/37)	0.556
Smoking	21.7% (15/69)	15.6% (5/32)	27.0% (10/37)	0.381
Fatty liver	30.4% (21/69)	18.8% (6/32)	40.5% (15/37)	0.068
HBsAg (+)	55.1% (38/69)	59.4% (19/32)	51.4% (19/37)	0.628
HCV RNA (+)	27.5% (19/69)	37.5% (12/32)	24.3% (9/37)	0.298
HBsAg (+) and HCV RNA (+)	2.9% (2/69)	3.1% (1/32)	2.7% (1/37)	1.000
Knodell inflammation score	3.7 ± 2.0	4.1 ± 1.7	3.4 ± 2.2	0.131
Ishak fibrosis score	4.0 ± 1.7	4.4 ± 1.7	3.6 ± 1.6	0.056
Liver cirrhosis	37.7% (26/69)	50% (16/32)	27.0% (10/37)	0.080
ALT (U/L)	53.2 ± 38.5	62.3 ± 42.6	45.3 ± 33.2	0.067
AST (U/L)	53.4 ± 31.9	60.1 ± 33.8	47.6 ± 29.4	0.104
Albumin (g/dL)	4.4 ± 0.3	4.3 ± 0.3	4.6 ± 0.3	0.002
Total bilirubin (mg/dL)	0.7 ± 0.4	0.7 ± 0.2	0.8 ± 0.4	0.143
Prolongation of prothrombin time (sec)	0.6 ± 0.7	0.7 ± 0.7	0.6 ± 0.7	0.436
Creatinine (mg/dL)	1.2 ± 1.2	1.5 ± 1.7	0.9 ± 0.4	0.086
α-fetoprotein (ng/mL)	425.9 ± 1219.4	589.6 ± 1469.6	284.2 ± 950.9	0.303
TNM stage (1:2:3)	22:36:11	7:14:11	15:22:0	< 0.001a
Follow up time (days)	928 ± 347	877.7 ± 373.7	970.8 ± 320.7	0.269
Mortality	10.1% (7/69)	18.8% (6/32)	2.7% (1/37)	0.044

Data are percentage or mean (standard deviation). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus. A 2-tailed independent t test was used for continuous variables between recurrence and non-recurrence groups. Comparisons of nominal values were by Fisher's exact test except TNM stage.

^aBy a Pearson Chi square test.